28.88
전일 마감가:
$28.81
열려 있는:
$29.93
하루 거래량:
1.44M
Relative Volume:
1.16
시가총액:
$3.06B
수익:
-
순이익/손실:
$-150.70M
주가수익비율:
-18.63
EPS:
-1.55
순현금흐름:
$-125.67M
1주 성능:
-4.12%
1개월 성능:
+1.44%
6개월 성능:
+97.54%
1년 성능:
+17.88%
엣지와이즈 Stock (EWTX) Company Profile
명칭
Edgewise Therapeutics Inc
전화
720-262-7002
주소
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
EWTX
Edgewise Therapeutics Inc
|
28.88 | 3.05B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
엣지와이즈 Stock (EWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-25 | 개시 | Goldman | Neutral |
| 2025-07-30 | 개시 | Raymond James | Strong Buy |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-04-30 | 개시 | Guggenheim | Buy |
| 2025-04-02 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-22 | 개시 | Stifel | Hold |
| 2024-11-22 | 개시 | Evercore ISI | Outperform |
| 2024-03-07 | 개시 | Piper Sandler | Overweight |
| 2023-05-01 | 개시 | Truist | Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-04-13 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-28 | 개시 | Goldman | Neutral |
모두보기
엣지와이즈 주식(EWTX)의 최신 뉴스
Edgewise Therapeutics to Present at Leerink Global Healthcare Conference on March 11, 2026 - geneonline.com
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 - Yahoo Finance
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Unpacking A 35.24% Upside Potential - DirectorsTalk Interviews
Becker muscular dystrophy drug prevents decline for 3.5 years in trial - Stock Titan
EWTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Edgewise Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - ChartMill
Citigroup Inc. Sells 186,446 Shares of Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Investor Mood: Will Edgewise Therapeutics Inc stock hit new highs in YEARJuly 2025 Trade Ideas & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Aug Reactions: Is Edgewise Therapeutics Inc stock forming a cup and handleTrade Exit Report & Community Verified Watchlist Alerts - baoquankhu1.vn
Artisan Partners Limited Partnership Reduces Stake in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Stock Rating Upgraded by HC Wainwright - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Assessing Edgewise Therapeutics (EWTX) Valuation As Earnings And Key Clinical Milestones Draw Closer - Sahm
Evercore Maintains Outperform, PT $45 for Edgewise Therapeutics (EWTX) Feb 2026 - Meyka
Q1 Earnings Estimate for EWTX Issued By HC Wainwright - MarketBeat
Analysts Offer Insights on Healthcare Companies: NovoCure (NVCR) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Edgewise Therapeutics (NASDAQ:EWTX) Posts Earnings Results - MarketBeat
Raymond James reiterates Strong Buy on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Edgewise Therapeutics stock - Investing.com UK
Edgewise Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Edgewise Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Stifel raises Edgewise Therapeutics stock price target on trial data timeline - Investing.com Canada
Edgewise Therapeutics Q4 Net Loss Widens From Previous Quarter - marketscreener.com
Earnings Flash (EWTX) Edgewise Therapeutics Posts Q4 Net Loss $0.47 a Share, vs. FactSet Est of $0.40 Loss - marketscreener.com
Edgewise Therapeutics, Inc. SEC 10-K Report - TradingView
Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi‑Year Returns And Recent Share Price Momentum - Yahoo Finance
Edgewise Therapeutics Q4 net loss widens vs Q3 as costs rise - TradingView
Edgewise (Nasdaq: EWTX) ups R&D spending as Q4 2025 loss widens - Stock Titan
BRIEF-Edgewise Therapeutics Q4 Operating Income USD -55.979 Million - TradingView
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs - PR Newswire
Edgewise Therapeutics stock hits 52-week high at $31.39 By Investing.com - Investing.com India
Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 52-Week HighStill a Buy? - MarketBeat
Edgewise Therapeutics stock hits 52-week high at $31.39 - Investing.com
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Target Price Suggests 26.84% Upside for Biotech Innovator - DirectorsTalk Interviews
How Edgewise Therapeutics Inc. (EWTX) Affects Rotational Strategy Timing - Stock Traders Daily
Edgewise Therapeutics (EWTX) Projected to Post Earnings on Monday - MarketBeat
Published on: 2026-02-21 16:05:11 - mfd.ru
Aberdeen Group plc Has $10.05 Million Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Forecast Cut: Will Edgewise Therapeutics Inc benefit from current market trendsJuly 2025 PostEarnings & Weekly Breakout Watchlists - baoquankhu1.vn
Aug Summary: Is FLIC on track to beat earningsWeekly Profit Recap & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Edgewise Therapeutics earnings on deck as pipeline advances By Investing.com - Investing.com South Africa
Edgewise Therapeutics earnings on deck as pipeline advances - Investing.com Nigeria
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: A High-Potential Biotech Play with 27% Upside - DirectorsTalk Interviews
GSA Capital Partners LLP Increases Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Will Edgewise Therapeutics Inc. stock gain from government policiesWeekly Trade Report & AI Forecast Swing Trade Picks - mfd.ru
Published on: 2026-02-16 03:13:40 - mfd.ru
Is Edgewise Therapeutics Inc. gaining market shareJuly 2025 Reactions & Community Trade Idea Sharing Platform - mfd.ru
What is Edgewise Therapeutics Inc.’s book value per share2025 Fundamental Recap & Reliable Entry Point Trade Alerts - mfd.ru
Edgewise Therapeutics (NASDAQ:EWTX) Upgraded at Wall Street Zen - MarketBeat
엣지와이즈 (EWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):